A Pilot Study of High-Dose Immunosuppression Followed by Infusion of CD34-Selected Autologous or Syngeneic Peripheral Blood Stem Cells for Treatment of Refractory Autoimmune Disorders
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 6
- 试验地点
- 1
- 主要终点
- Mortality
研究概览
简要总结
OBJECTIVES: I. Determine the safety and long term complications of total body irradiation in combination with cyclophosphamide, anti-thymocyte globulin, and autologous CD34-selected peripheral blood stem cell (PBSC) transplantation in children with refractory autoimmune disorders.
II. Determine the efficacy of this treatment regimen in these patients. III. Determine the reconstitution of immunity after autologous CD34-selected PBSC transplantation in these patients.
IV. Determine engraftment of autologous CD34-selected PBSC in these patients.
详细描述
PROTOCOL OUTLINE: This is a multicenter study. Patients receive filgrastim (G-CSF) subcutaneously daily until peripheral blood stem cell (PBSC) collection is completed. CD34+ cells are separated from the rest of the PBSCs.
Patients undergo total body irradiation twice daily on days -5 and -4. Patients receive anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5 and cyclophosphamide IV on days -3 and -2. CD34-selected PBSCs are reinfused on day 0. Patients receive G-CSF IV daily beginning on day 0 and continuing until blood counts recover.
Patients are followed annually for 5 years and then every 5 years thereafter.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics--
- •Diagnosis of 1 of the following based on American College of Rheumatology (ACR) Criteria: Severe juvenile rheumatoid arthritis (systemic onset or polyarticular course) Juvenile systemic lupus erythematosus Systemic sclerosis Dermatomyositis
- •Refractory to standard or aggressive therapy OR unacceptable toxicity from standard therapy
- •Reasonable expectation of possible improvement as evidenced by a good potential for rehabilitation therapy and adequate social factors
- •No serious CNS damage that would preclude significant functional recovery
- •-Prior/Concurrent Therapy--
- •Chemotherapy: At least 4 weeks since prior methotrexate or cyclophosphamide
- •Endocrine therapy: At least 4 weeks since prior intra-arterial steroids Juvenile rheumatoid arthritis patients should continue steroids without taper throughout mobilization and harvest of stem cells If receiving corticosteroids, must be continued without taper
- •At least 4 weeks since prior anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs) or sulfasalazine
- •At least 4 weeks since prior cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, penicillamine, or etanercept
- •-Patient Characteristics--
- •Life expectancy: At least 30 days
- •Hematopoietic: Absolute neutrophil count at least 1,000/mm3 OR Platelet count at least 100,000/mm3 No bone marrow aspirate or biopsy consistent with production defect (depletion of neutrophil precursors or megakaryocytes) No myelodysplasia
- •Hepatic: Bilirubin no greater than 2.5 mg/dL AST no greater than 300 U/L on two sequential tests No severe liver dysfunction within past month No active hepatitis A, B, or C
- •Renal: No end-stage glomerulonephritis or renal disease Creatinine clearance at least 40 mL/min
- •Cardiovascular: No uncontrolled malignant arrhythmia No New York Heart Association class III or IV congestive heart failure Ejection fraction at least 50%
- •Pulmonary: DLCO at least 45% (DLCO at least 70% for patients with pulmonary disease caused by documented processes other than primary autoimmune disorder, such as infectious pneumonia or aspiration pneumonia) No severe pulmonary hypertension (PAP greater than 50) without potential for significant improvement
- •No medical or psychosocial reasons that would make hematopoietic stem cell collection intolerable
- •No increased anesthetic risks
- •No fever higher than 39 degrees C
- •No positive serology for toxoplasmosis
- •No active life threatening infection not responsive to therapy
- •No other disease or organ dysfunction that would limit survival
- •No known hypersensitivity to murine or equine proteins
- •No known primary immunodeficiency disease HIV negative
排除标准
- 未提供
研究组 & 干预措施
1
Participants will receive a stem cell transplant.
干预措施: Stem Cell Transplantation (Procedure)
1
Participants will receive a stem cell transplant.
干预措施: CD34 selection (Device)
结局指标
主要结局
Mortality
时间窗: Annually for 5 years and then every 5 years thereafter
次要结局
- Immune reconstitution, engraftment, efficacy, late-effects(Annually for 5 years and then every 5 years thereafter)